We are live on ! Find out more
ARMC

American Research & Management Company Portfolio holdings

AUM $362M
1-Year Est. Return 8.06%
This Fund
S&P 500
This Quarter Est. Return
-4.87%
1 Year Est. Return
-8.06%
3 Year Est. Return
+35.06%
5 Year Est. Return
+60.88%
10 Year Est. Return
AUM
$362M
AUM Growth
-$26.9M
Cap. Flow
-$2.99M
Cap. Flow %
-0.83%
Top 10 Hldgs %
32.46%
Holding
471
New
47
Increased
54
Reduced
92
Closed
46

Top Buys

Rank Stock Value
1
ADBE icon
Adobe
ADBE
+$730K
2
PYPL icon
PayPal
PYPL
+$427K
3
FDX icon
FedEx
FDX
+$331K
4
NVDA icon
NVIDIA
NVDA
+$260K
5
FCX icon
Freeport-McMoran
FCX
+$230K

Top Sells

Rank Stock Value
1
OKTA icon
Okta
OKTA
+$2M
2
AAPL icon
Apple
AAPL
+$486K
3
IBM icon
IBM
IBM
+$472K
4
DOV icon
Dover
DOV
+$250K
5
ITW icon
Illinois Tool Works
ITW
+$243K

Sector Composition

Rank Sector Weight
1 Technology 22.52%
2 Healthcare 14.01%
3 Financials 12.9%
4 Consumer Staples 12.61%
5 Energy 7.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PBE icon
351
Invesco Biotechnology & Genome ETF
PBE
$282M
$3K ﹤0.01%
50
PHO icon
352
Invesco Water Resources ETF
PHO
$1.98B
$3K ﹤0.01%
70
PICK icon
353
iShares MSCI Global Metals & Mining Producers ETF
PICK
$2.19B
$3K ﹤0.01%
+88
New +$3.16K
TIP icon
354
iShares TIPS Bond ETF
TIP
$14.5B
$3K ﹤0.01%
30
ZM icon
355
Zoom
ZM
$26.7B
$3K ﹤0.01%
+36
New +$3.43K
ERF
356
DELISTED
Enerplus Corporation
ERF
$3K ﹤0.01%
200
OPNT
357
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$3K ﹤0.01%
300
ABEV icon
358
Ambev
ABEV
$47.4B
$2K ﹤0.01%
+783
New +$2.22K
ACAD icon
359
Acadia Pharmaceuticals
ACAD
$4.35B
$2K ﹤0.01%
100
BBC icon
360
Virtus Biotech Clinical Trials ETF
BBC
$47.3M
$2K ﹤0.01%
100
C icon
361
Citigroup
C
$223B
$2K ﹤0.01%
40
CCL icon
362
Carnival Corporation Ltd
CCL
$37.1B
$2K ﹤0.01%
300
DNA icon
363
Ginkgo Bioworks
DNA
$487M
$2K ﹤0.01%
18
GNOM icon
364
Global X Genomics & Biotechnology ETF
GNOM
$78.6M
$2K ﹤0.01%
38
GS icon
365
Goldman Sachs
GS
$309B
$2K ﹤0.01%
+7
New +$2.27K
ISRG icon
366
Intuitive Surgical
ISRG
$128B
$2K ﹤0.01%
+12
New +$2.58K
PIO icon
367
Invesco Global Water ETF
PIO
$271M
$2K ﹤0.01%
70
VTRS icon
368
Viatris
VTRS
$20.5B
$2K ﹤0.01%
284
-13
-4% -$128
DJT icon
369
Trump Media & Technology Group
DJT
$2.65B
$2K ﹤0.01%
104
AVDL
370
DELISTED
Avadel Pharmaceuticals
AVDL
$1K ﹤0.01%
100
BKCH icon
371
Global X Blockchain ETF
BKCH
$219M
$1K ﹤0.01%
25
SRTA
372
Strata Critical Medical Inc
SRTA
$445M
$1K ﹤0.01%
125
BUD icon
373
AB InBev
BUD
$156B
$1K ﹤0.01%
+18
New +$932
CCI icon
374
Crown Castle
CCI
$32.4B
$1K ﹤0.01%
+8
New +$1.37K
DOCU
375
DocuSign
DOCU
$10.1B
$1K ﹤0.01%
+27
New +$1.69K

Similar funds

American Research & Management Company's Q3 2022 Portfolio in Review

As of Q3 2022, American Research & Management Company held 471 positions worth $362M, down 6.9% from $389M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

American Research & Management Company's Q3 2022 filing shows 47 new, 54 increased, 92 reduced and 46 closed positions. Its largest new stake was iShares iBoxx $ Investment Grade Corporate Bond ETF: 380 shares worth $39K. The largest sale was Okta, an estimated $2M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.

  • American Research & Management Company's largest Q3 2022 buy was iShares iBoxx $ Investment Grade Corporate Bond ETF: 380 shares worth $39K.
  • American Research & Management Company added most to Adobe in Q3 2022, an estimated $730K increase.
  • American Research & Management Company's biggest Q3 2022 reduction was Okta, cutting an estimated $2M.
  • American Research & Management Company fully exited BlackRock Taxable Municipal Bond Trust in Q3 2022, selling an estimated $27K.
  • American Research & Management Company's ten largest holdings make up 32% of its $362M portfolio in Q3 2022.
  • American Research & Management Company opened 47 new positions and closed 46 in Q3 2022.
  • American Research & Management Company's portfolio value fell 6.9% quarter-over-quarter to $362M.

Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.